Myosteatosis is associated with coronary artery calcification in patients with type 2 diabetes

doi:10.4239/wjd.v15.i3.429

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (841)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-1) series.

Item

Count

PDF

WORD

HTML

492

Figures (1-5)

Tables (1-1)

Sum=661

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=129

Mar 15, 2024 (publication date) through Apr 29, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Diabetes. Mar 15, 2024; 15(3): 429-439
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.429

Table 1 Characteristics of the study population

Variables	All patients (n = 652)	T2DM group (n = 485)	T2DM + SCAC group (n = 167)	P value
Male (%)	425 (65.2)	312 (64.3)	113 (67.7)	0.453
Age (yr)	55.95 ± 10.87	53.75 ± 10.62	62.34 ± 8.94	< 0.001
Diabetes duration (yr)	8.97 ± 7.13	7.87 ± 6.36	12.15 ± 8.22	< 0.001
Body mass index (kg/m²)	25.79 ± 3.66	25.87 ± 3.61	25.56 ± 3.79	0.358
Fasting glucose (mmol/L)	7.67 ± 2.23	7.53 ± 2.19	8.09 ± 2.31	0.018
Fasting C peptide (ng/mL)	2.27 ± 1.06	2.25 ± 0.97	2.32 ± 1.30	0.581
Hemoglobin A1c (%)	8.71 ± 2.19	8.76 ± 2.23	8.59 ± 2.06	0.384
HOMA2-β	166.51 ± 93.75	169.89 ± 92.31	155.97 ± 97.78	0.170
HOMA2-IR	5.62 ± 2.67	5.55 ± 2.48	5.84 ± 3.20	0.314
Hemoglobin (g/L)	138.69 ± 21.98	139.77 ± 22.44	135.52 ± 20.30	0.032
Albumin (g/L)	43.14 ± 4.51	43.34 ± 4.31	42.55 ± 5.01	0.071
Alanine transaminase (U/L)	18.20 (13.30, 27.80)	19.35 (13.93, 28.90)	15.90 (12.20, 21.90)	< 0.001
Creatinine (mg/L)	61.38 ± 16.65	60.30 ± 15.78	64.49 ± 18.66	0.010
Blood urea nitrogen (mg/dL)	5.65 ± 1.59	5.52 ± 1.45	6.04 ± 1.90	< 0.001
Cystatin C (mg/L)	1.00 ± 0.29	0.97 ± 0.25	1.11 ± 0.35	< 0.001
Triglycerides (mmol/L)	1.44 (0.98, 2.24)	1.44 (0.98, 2.32)	1.39 (0.95, 1.99)	0.199
Total cholesterol (mmol/L)	4.63 ± 1.56	4.70 ± 1.33	4.44 ± 2.09	0.059
HDL (mmol/L)	1.18 ± 0.38	1.18 ± 0.40	1.16 ± 0.33	0.506
LDL (mmol/L)	2.77 ± 1.18	2.86 ± 1.22	2.53 ± 1.05	0.002
FT3 (pmol/L)	4.53 ± 1.40	4.61 ± 1.57	4.30 ± 0.71	0.016
FT4 (pmol/L)	16.58 ± 3.04	16.57 ± 3.08	16.59 ± 2.91	0.943
TSH (pmol/L)	2.25 ± 1.41	2.24 ± 1.37	2.30 ± 1.54	0.597
SBP (mmHg)	136.23 ± 19.06	136.10 ± 19.82	136.63 ± 16.72	0.736
DBP (mmHg)	81.13 ± 13.00	81.19 ± 13.43	80.95 ± 11.68	0.840
MMA (HU)	36.41 ± 7.29	37.24 ± 7.23	34.02 ± 6.95	< 0.001
Myosteatosis (%)	309 (47.4)	199 (41.0)	110 (65.9)	< 0.001
CHD (%)	166 (25.5)	96 (19.8)	70 (41.9)	< 0.001
SMI (cm²/m²)	46.71 ± 9.31	47.18 ± 9.30	45.34 ± 9.23	0.027
FMI (kg/m²)	8.56 ± 1.79	8.51 ± 1.79	8.68 ± 1.79	0.290
Cigarette smoking (%)	261 (40.0)	170 (35.1)	91 (54.5)	< 0.001
Alcohol intake (%)	295 (45.2)	204 (42.1)	91 (54.5)	0.007
Dyslipidemia (%)	369 (56.6)	282 (58.1)	87 (52.1)	0.176
Hypertension (%)	308 (47.2)	215 (44.3)	93 (55.7)	0.012
Diabetic complications (%)	564 (86.5)	410 (84.5)	154 (92.2)	0.012
DN (%)	247 (37.9)	169 (34.8)	78 (46.7)	0.007
DPN (%)	498 (76.4)	362 (74.6)	136 (81.4)	0.091
LEAD (%)	105 (16.1)	73 (15.1)	32 (19.2)	0.223
DR (%)	185 (28.4)	118 (24.3)	67 (40.1)	< 0.001
Antidiabetics (%)	569 (87.3)	411 (84.7)	158 (94.6)	0.001
Insulin (%)	249 (38.2)	172 (35.5)	77 (46.1)	0.016
Metformin (%)	434 (66.6)	310 (63.9)	124 (74.3)	0.017
Sulphonylureas (%)	312 (47.9)	230 (47.7)	82 (49.1)	0.720
Acarbose (%)	257 (39.4)	180 (37.1)	77 (46.1)	0.044
Others (%)	167 (25.6)	120 (24.7)	47 (28.1)	0.411
Lipid-lowering drugs (%)	140 (21.5)	84 (17.3)	56 (33.5)	< 0.001
Statins (%)	131 (20.1)	75 (15.5)	56 (33.5)	< 0.001
Fibrates (%)	9 (1.4)	9 (1.9)	0 (0.0)	0.121
Antihypertensive drugs (%)	237 (36.3)	158 (32.6)	79 (47.3)	0.001
ACE inhibitors (%)	33 (5.1)	20 (4.1)	13 (7.8)	0.068
ARBs (%)	105 (16.1)	71 (14.6)	34 (20.4)	0.088
Calcium antagonists (%)	134 (20.6)	89 (18.4)	45 (26.9)	0.020
β-Blockers (%)	64 (9.8)	36 (7.4)	28 (16.8)	0.001
Diuretics (%)	32 (4.9)	22 (4.5)	10 (6.0)	0.533
Aspirin (%)	145 (22.2)	84 (17.3)	61 (36.5)	< 0.001

T2DM: Type 2 diabetes mellitus; SCAC: Severe coronary artery calcification; HOMA2-β: Homeostasis model assessment 2 of beta-cell function; HOMA2-IR: Homeostasis model assessment 2 of insulin resistance; HDL: High-density lipoproteins; LDL: Low-density lipoproteins; FT3: Free triiodothyronine; FT4: Free thyroxine; TSH: Thyroid-stimulating hormone; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; CHD: Coronary heart disease; SMI: Skeletal muscle index; MMA: Mean skeletal muscle attenuation; FMI: Fat mass index; DN: Diabetic nephropathy; DPN: Diabetic peripheral neuropathy; LEAD: Lower extremity arterial disease; DR: Diabetic retinopathy; ACE: Angiotensin-converting enzyme; ARB: Angiotensin II receptor blocker.

Citation: Liu FP, Guo MJ, Yang Q, Li YY, Wang YG, Zhang M. Myosteatosis is associated with coronary artery calcification in patients with type 2 diabetes. World J Diabetes 2024; 15(3): 429-439
URL: https://www.wjgnet.com/1948-9358/full/v15/i3/429.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i3.429